

Bexel Pharmaceuticals, Inc.
Balance Sheet at March 31, 2023 (Provisional)

		March 31, 2023
ASSETS		
Current Assets		
Checking/Savings		
1010 · WFB #0131 - New Checking		5.00
1000 · WFB #4602 - Old Checking		0.00
Total Checking/Savings		5.00
Other Current Assets		
1620 · Receivable - Orchid		0.00
Total Other Current Assets		0.00
Total Current Assets		5.00
Fixed Assets		
1100 · Laboratory Equipment		
1101 · Laboratory Equip-Accum Depreciation		-8,886.78
1102 · Laboratory Equipment Cost		8,886.78
Total 1100 · Laboratory Equipment		0.00
1200 · Computers and Office Equip		
1201 · Computers-Accum Depreciation		-20,976.08
1202 · Computers Cost		20,976.08
Total 1200 · Computers and Office Equip		0.00
Total Fixed Assets		0.00
TOTAL ASSETS		5.00
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Other Current Liabilities		
2100 · Payroll Liabilities		1,27,169.05
2170 · Retirement Fidelity FPRS		2.20
Total Other Current Liabilities		1,27,171.25
Total Current Liabilities		1,27,171.25
Long Term Liabilities		
2135 · Due to OrchidPharma, Inc.		49,989.00
2130 · Intercompany - Orchid		54,71,500.00
Total Long Term Liabilities		55,21,489.00
Total Liabilities		56,48,660.25
Equity		
3100 · Common Stock		21,002.02
3150 · Preferred Stock		10,000.00
3160 · Series B Preferred		4,893.25
3200 · Additional Paid in Capital		1,83,38,881.27
3400 · Treasury Stock		-13,00,460.94
3900 · Retained Earnings		-2,27,22,970.85
Total Equity		-56,48,655.25
TOTAL LIABILITIES & EQUITY		5.00

BEXEL Pharmaceuticals, Inc.
Profit & Loss
April 2022 through March 2023

	Accrual Basis
	Apr' 22 - Mar 23
Net Income	<u><u>0.00</u></u>
Bank Charges	0.00
IRS Charges	<u>0.00</u>
	<u>0.00</u>
Net Loss for the period	<u><u>0.00</u></u>